![](/img/cover-not-exists.png)
Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from 2 phase III trials
Paul, C., Guenther, L., Torii, H., Sofen, H., Burge, R., Lin, C.Y., Potts Bleakman, A., Mallbris, L., Poulin, Y.Language:
english
Journal:
Journal of the European Academy of Dermatology and Venereology
DOI:
10.1111/jdv.14581
Date:
September, 2017
File:
PDF, 643 KB
english, 2017